Janux Therapeutics, Inc. (JANX)
13.80
-0.03
(-0.22%)
USD |
NASDAQ |
Dec 31, 16:00
13.74
-0.06
(-0.43%)
After-Hours: 20:00
Janux Therapeutics Cash from Investing (Quarterly): 8.306M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Eli Lilly & Co. | -2.983B |
| Stoke Therapeutics, Inc. | 9.094M |
| Ionis Pharmaceuticals, Inc. | 91.34M |
| MannKind Corp. | -25.06M |
| Madrigal Pharmaceuticals, Inc. | -207.00M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -12.86M |
| Cash from Financing (Quarterly) | 0.493M |
| Free Cash Flow | -71.40M |
| Free Cash Flow Per Share (Quarterly) | -0.2088 |
| Free Cash Flow to Equity (Quarterly) | -13.42M |
| Free Cash Flow to Firm (Quarterly) | -12.95M |
| Free Cash Flow Yield | -8.53% |